Ozempic vs Invokana
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| US Ozempic | US Invokana | |
|---|---|---|
| Generic name | semaglutide | canagliflozin |
| Drug class | GLP-1 Receptor Agonist | SGLT2 Inhibitor |
| Treats | Type 2 diabetes | Type 2 diabetes, diabetic kidney disease |
| Category | Diabetes | Diabetes |
| Manufacturer | Novo Nordisk | Janssen |
| Year approved | 2017 | 2013 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $420M | $110M |
| Common side effects | Nausea, Vomiting, Diarrhea, Abdominal pain | Genital yeast infections, Urinary tract infections, Increased urination, Risk of leg/foot amputation |
Frequently asked questions
Is Ozempic or Invokana better?
Neither is universally "better." Ozempic (semaglutide) and Invokana (canagliflozin) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Ozempic and Invokana?
Ozempic is a GLP-1 Receptor Agonist made by Novo Nordisk, while Invokana is a SGLT2 Inhibitor made by Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Ozempic has the larger estimated TV advertising budget of the two.